[go: up one dir, main page]

WO2019119049A1 - Procédé de prédiction d'état de répondeur à une thérapie médicamenteuse et procédés de traitement - Google Patents

Procédé de prédiction d'état de répondeur à une thérapie médicamenteuse et procédés de traitement Download PDF

Info

Publication number
WO2019119049A1
WO2019119049A1 PCT/AU2018/051371 AU2018051371W WO2019119049A1 WO 2019119049 A1 WO2019119049 A1 WO 2019119049A1 AU 2018051371 W AU2018051371 W AU 2018051371W WO 2019119049 A1 WO2019119049 A1 WO 2019119049A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
lipid
species
lipid species
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2018/051371
Other languages
English (en)
Inventor
Peter Meikle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baker IDI Heart and Diabetes Institute
Original Assignee
Baker IDI Heart and Diabetes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017905095A external-priority patent/AU2017905095A0/en
Application filed by Baker IDI Heart and Diabetes Institute filed Critical Baker IDI Heart and Diabetes Institute
Publication of WO2019119049A1 publication Critical patent/WO2019119049A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the specification relates to methods for stratifying an individual as a likely therapy responder or likely therapy non-responder to HMG-CoA reductase inhibitors wherein a therapy responder displays a reduced risk of a cardiovascular event and a therapy non-responder does not, using a lipid profiling approach.
  • the description enables stratification of individuals into treatment categories and in part facilitates clinical management of individuals identified as at risk for future cardiovascular events. Small molecule and lipid chemistry and lipidomics are employed to characterise lipid classes and species in biological samples.
  • the specification relates to methods of treatment including methods of reducing risk of a cardiovascular event.
  • Lipids are among the least studied molecules of the metabalome. Levels of certain plasma lipid species have been associated with future cardiovascular events but lipid profiling on the whole is in its infancy. It is certainly not known to select a profile of plasma lipid species before or after HMG-CoA reductase inhibitor treatment that is predictive of future cardiovascular events.
  • the present disclosure enables a method for determining the likelihood that a HMG-CoA reductase inhibitor treatment will reduce the risk of a cardiovascular event in an individual, the method comprising (i) detecting a level of one or two or more non steroidal lipid species in a biological sample obtained from the individual at a time point before or after treatment; (ii) comparing the level one or two or more lipid species, or a ratio of the level of two lipid species, from step (i) in the sample to a reference level or ratio for the lipid species; and (iii) determining whether the treatment is likely or not to reduce the risk of the cardiovascular event in the individual on the basis of the comparison.
  • the cardiovascular event is selected from one or more of the group consisting of coronary heart disease, atherosclerosis, stroke, unstable angina, cardiomyopathy, cardiovascular disease death, myocardial infarction, ischaemic heart disease, heart failure, hypertensive heart disease, inflammatory heart disease and valvular heart disease.
  • the lipid species is/are selected from a lipid class or subclass selected from the group consisting of dihydroceramide (Cer(dl8:0)), ceramide (Cer(dl8: l)), monohexocylceramide (HexCer), dihexosylceramide (Hex2Cer), trihexosylceramide (Hex3Cer), GM3 ganglioside (GM3), sphingomyelin (SM), phosphatidylcholine (PC), alkylphosphatidylcholine (PC(O)), alkenylphosphatidylcholine (PC(P)), lysophosphatidylcholine (LPC), lysoalkylphosphatidylcholine (LPC(O)), phosphatidylethanolamine (PE), alkylphosphatidylethanolamine (PE(O)), alkenylphosphatidylethanolamine (PE(P)), ly
  • the lipid species is a phospholipid selected from the group consisting of lysophosphatidylcholine, sphingomyelin, phosphatidylinositol, phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, and ly sophosphati dy 1 ethal ol amine .
  • the present assay methods include methods the employ statin administration and determining the change in lipid species after administration.
  • the present methods also include assay methods that do not employ statin administration and/or determining the change in lipid species as a result of statin administration, and instead predict a risk reduction based on the current lipid profile of the individual who is not taking statins.
  • step (i) is conducted before or without a HMG-CoA reductase inhibitor treatment.
  • the one, two or more lipid species in step (ii) are selected from Hex2Cer(l6:0), LPC(l6: l), LPC(20: l), PC(3l : l), PC(32:2), PC(32:3), PC(33:2), PC(33:3), PC(34:0), PC(34: l), PC(35:3), PC(36:3), LPC(0-22: l), LPC(0-24: l), PC(0-34:3), PI(34:0), PI(36:4), PI(38:2), PI(38:6), SM(34: l), SM(35:2), SM(36: l), SM(36:2), SM(36:3), SM(37:2), and TG(l8:0/l8:0/l8:0).
  • a lipid species or the lipid species in at least one ratio of the level of two lipid species in step (ii) are selected from Hex2Cer(l6:0), LPC(l6: l), LPC(20: l), PC(3 l : l), PC(32:2), PC(32:3), PC(33:2), PC(33:3), PC(34:0), PC(34: l), PC(35:3), PC(36:3), LPC(0-22: l), LPC(0-24:l), PC(0-34:3), PI(34:0), PI(36:4), PI(38:2), PI(38:6), SM(34: l), SM(35:2), SM(36: l), SM(36:2), SM(36:3), SM(37:2), and TG(l8:0/l8:0/l8:0).
  • the one, two or more lipid species in step (ii) are selected from LPC(l6: l), LPC(20: l), PC(32:2), LPC(0-22: l), PI(36:4), PI(38:2), PI(38:6), SM(35:2), SM(36: l), SM(36:2), SM(37:2), and TG(l8:0/l8:0/l8:0).
  • a lipid species or the lipid species in at least one ratio of the level of two lipid species in step (ii) are selected from LPC(l6: l), LPC(20: l), PC(32:2), LPC(0-22: l), PI(36:4), PI(38:2), PI(38:6), SM(35:2), SM(36: l), SM(36:2), SM(37:2), and TG(l8:0/l8:0/l8:0).
  • step (i) is conducted after a HMG-CoA reductase inhibitor treatment.
  • this allows a lipid profile to be determined after a HMG- CoA reductase inhibitor treatment and compared to that before HMG-CoA reductase inhibitor treatment.
  • the present description provides a method for determining the likelihood that a HMG-CoA reductase inhibitor treatment will reduce the risk of a cardiovascular event in an individual, the method comprising (i) detecting a level of one or two or more non-steroidal lipid species in a biological sample obtained from the individual at a time point after treatment; (ii) comparing the level one or two or more lipid species, or a ratio of the level of two lipid species, from step (i) in the sample to a reference level or ratio for the lipid species; and (iii) determining whether the treatment is likely or not to reduce the risk of the cardiovascular event in the individual on the basis of the comparison.
  • At least one lipid species is a lipid species such as a phospholipid species, or a phosphatidylinositol lipid species, that displays a reduced level after the treatment in reference individuals who also show a reduced risk of a cardiovascular event as a result of the treatment.
  • At least one lipid species is a phosphatidylcholine species or a lipid comprising an omega 6 fatty acid that displays an elevated level as a result of the treatment in reference individuals who also show a reduced risk of a cardiovascular event as a result of the treatment.
  • the omega 6 fatty acid is selected from 18:3, 20:3, 20:4, 22:4, 24:4, 24:5 and 22:5.
  • the lipid species is PC(38.4).
  • the method comprises detecting the level of two or more lipid species in the sample.
  • the lipid species are selected from two or more different lipid classes or subclasses.
  • a ratio in step (ii) is between the level of two lipid species selected from Figure 8.
  • a ratio in step (ii) is between the level of two lipid species selected from a lipid classes or sub classes selected from Figure 9.
  • a ratio in step (ii) is between (a) the level of a phosphatidylinositol species that displays reduced levels as a result of the treatment in reference individuals who also show a reduced the risk of a cardiovascular event as a result of the treatment and (b) a phosphatidylcholine species that displays an elevated level as a result of the treatment in reference individuals who also show a reduced risk of a cardiovascular event as a result of the treatment.
  • species in a) is PI(36:3) or PI(38:4).
  • the species in b) is PC(38:4).
  • a ratio in step (ii) is between the level of PI(36:3) and PC(38:4) and/or between the level of PI(36:2) and PC(38:4).
  • the disclosure provides a method for stratifying an individual as a likely statin therapy responder or likely therapy non-responder with respect to a HMG-CoA reductase inhibitor treatment regimen comprising ascertaining the likelihood that the HMG-CoA reductase inhibitor treatment regimen will reduce the risk of a cardiovascular event in the individual according to the methods described herein.
  • the stratifying method comprises (i) detecting a level of one or two or more non-steroidal lipid species in a biological sample obtained from the individual at a time point before or after treatment; (ii) comparing the level one or two or more lipid species, or a ratio of the level of two lipid species, from step (i) in the sample to a reference level or ratio for the lipid species; and (iii) determining whether the treatment is likely or not to reduce the risk of the cardiovascular event in the individual on the basis of the comparison.
  • a method of screening for an agent that reduces the risk of a cardiovascular event comprising screening an agent in a test subject for an ability to develop a therapy responder profile according to the assay method as described herein.
  • the method of screening for an agent that reduces the risk of a cardiovascular event comprises screening an agent for an ability to reduce the level of a phophosphatidylinositol lipid species in a test subject.
  • the description enables a method of treatment or prophylaxis of an individual comprising administering an HMG-CoA reductase inhibitor treatment regimen to reduce the risk of a cardiovascular event, the method comprising administering an HMG-CoA reductase inhibitor treatment regimen to the individual after ascertaining the likelihood that the HMG-CoA reductase inhibitor treatment regimen will reduce the risk of a cardiovascular event in the individual according to the assay method described herein.
  • the description enables a method of treatment or prophylaxis of an individual to reduce the/their risk of a cardiovascular event, the method comprising administering an HMG-CoA reductase inhibitor treatment regimen in combination with fatty acid supplementation such with a lipid comprising an omega-6 fatty acid or arachidonic acid.
  • the method comprises administering fatty acid supplementation with a lipid comprising an omega-6 fatty acid or arachidonic acid to an individual at risk of a cardiovascular event, who has previously been administered an HMG-CoA reductase inhibitor.
  • the omega 6 fatty acid is selected from Cl8:2, 18:3, 20:3, 20:4, 22:4, 24:4, 24:5 and 22:5.
  • the omega 6 fatty acid is arachidonic acid.
  • the description provides a method of treating an individual at risk of a cardiovascular event, the method comprising administering an agent that lowers plasma levels of phosphatidylinositol in the individual.
  • the agent inhibits phosphatidylinositol synthase.
  • the agent is selected from one or more of: an inositol analogue, an anti-CDIPT antibody or antigen binding part thereof that is a phosphatidylinositol synthase inhibitor, an aptamer, small molecule, an antisense, sgRNA or iRNA, zinc in the case of zinc deficiency, and sorbitol or glucose.
  • an inositol analogue an anti-CDIPT antibody or antigen binding part thereof that is a phosphatidylinositol synthase inhibitor, an aptamer, small molecule, an antisense, sgRNA or iRNA, zinc in the case of zinc deficiency, and sorbitol or glucose.
  • Illustrative inhibitors include inostamycin and 8- hexachl orocy cl ohexane .
  • Figure 2 Association of change in lipid concentration with future cardiovascular events within treatment group.
  • Hazard Ratio denotes hazard ratio per unit interquartile range
  • 95% Cl denotes 95% of confidence interval.
  • Models were adjusted for age, BMI, cholesterol at baseline, high density lipoprotein at baseline, triglycerides at baseline, current smoking, systolic blood pressure, fasting glucose, atrial fibrillation, gender, stroke history, diabetes history, history of hypertension, nature of prior acute coronary syndrome, revascularization, eGFR, dyspnea grade, angina grade, white blood cell count, peripheral vascular disease, aspirin at baseline, change in LDL-C, and baseline level of a given lipid species.
  • P-values were corrected for multiple comparisons using Benjamini-Hochberg method. Lipid species with P-value ⁇ 0.0l are presented.
  • Figure 3 Association of change in lipid concentration with future cardiovascular death within treatment group.
  • Hazard Ratio denotes hazard ratio per unit interquartile range
  • 95% Cl denotes 95% of confidence interval.
  • Models were adjusted for age, BMI, cholesterol at baseline, high density lipoprotein at baseline, triglycerides at baseline, current smoking, systolic blood pressure, fasting glucose, atrial fibrillation, gender, stroke history, diabetes history, history of hypertension, nature of prior acute coronary syndrome, revascularization, eGFR, dyspnea grade, angina grade, white blood cell count, peripheral vascular disease, aspirin at baseline, change in LDL-C, and baseline level of a given lipid specie.
  • P-values were corrected for multiple comparisons using Benjamini-Hochberg method. Lipid species with P-value ⁇ 0.0l are presented.
  • Figure 4 Association of treatment with future cardiovascular events after adjustment for changes in LDL-C and lipid concentration.
  • the base model was adjusted for age, BMI, cholesterol at baseline, high density lipoprotein at baseline, triglycerides at baseline, current smoking, systolic blood pressure, fasting glucose, atrial fibrillation, gender, stroke history, diabetes history, history of hypertension, nature of prior acute coronary syndrome, revascularization, eGFR, dyspnea grade, angina grade, white blood cell count, peripheral vascular disease and aspirin at baseline.
  • * denotes treatment effect relative to the base + change in LDL-C model
  • Randomized treatment effect represents the median over 1000 randomizations and the 5th and 95th percentiles.
  • Figure 5 Association of treatment with future cardiovascular death after adjustment for changes in LDL-C and lipid concentration.
  • the base model was adjusted for age, BMI, cholesterol at baseline, high density lipoprotein at baseline, triglycerides at baseline, current smoking, systolic blood pressure, fasting glucose, atrial fibrillation, gender, stroke history, diabetes history, history of hypertension, nature of prior acute coronary syndrome, revascularization, eGFR, dyspnea grade, angina grade, white blood cell count, peripheral vascular disease and aspirin at baseline.
  • * denotes treatment effect relative to the base + change in LDL-C model
  • Randomized treatment effect represents the median over 1000 randomizations and the 5th and 95th percentiles.
  • Figure 6 Change in the lipid ratio and LDL-C in quartiles of the treatment group stratified on the change in the lipid ratio.
  • the treatment group was stratified into quartiles using the change in the lipid ratio PI(36:2)/PC(38:4).
  • Panel A shows the median change of LDL-C in each quartile with the interquartile range shown by the whiskers. The median change and interquartile range of the control group is also shown for reference (open squares).
  • Panel B shows the median change of the lipid ratio in each quartile with the interquartile range shown by the whiskers. The median change and interquartile range of LDL-C in the control group is also shown for reference (open squares).
  • Figure 7 Association of treatment with future cardiovascular events and cardiovascular death in quartiles of change in lipid ratio (PI(36:2)/PC(38:4)) in the statin treatment group.
  • the samples in each quartile of the delta lipid ratio in statin treatment were combined with all the samples in the placebo group and a cox regression analysis was performed to find the hazard ratio of treatment for cardiovascular events and death.
  • Base models included the variables: age, BMI, cholesterol at baseline, high density lipoprotein at baseline, triglycerides at baseline, current smoking, systolic blood pressure, fasting glucose, atrial fibrillation, gender, stroke history, diabetes history, history of hypertension, nature of prior acute coronary syndrome, revascularization, eGFR, dyspnea grade, angina grade, white blood cell count, peripheral vascular disease and aspirin at baseline.
  • Figure 8 tabulates the results showing the mean percentage change of lipid species levels in treatment and control groups.
  • the index for superscripted numbers in column descriptions are as follows: 1 Median concentration and Inter-quartile range (mM); 2 Standard-deviation; 3 Uncorrected P-value; 4 P-values are corrected for multiple comparisons using the Benjamini- Hochberg approach.
  • P-values are color coded as follows: P-value ⁇ 0.00l red (grey); 0.00l ⁇ P- value ⁇ 0.0l yellow (palest grey); 0.0l ⁇ P-value ⁇ 0.05 green (paler grey).
  • Figure 9 tabulates the results showing the association of treatment with percentage change in lipid species.
  • the index for superscripted numbers in column descriptions are as follows: 1 Model 1 was adjusted for: age, sex, body mass index; 2 Model 2 was adjusted for: age, sex, body mass index and the percentage changes in total cholestrol, HDL-C and triglicerides;
  • Beta coefficient denotes the difference in percentage changes (from baseline to follow-up) between treatment and placebo groups; 4 95% Cl denotes 95% of confidence interval (Lower and Upper limits); 5 P-values are corrected for multiple comparisons using the Benjamini-Hochberg approach. P-values are color coded as follows: P-value ⁇ 0.00l red (grey) ; 0.00l ⁇ P-value ⁇ 0.0l yellow (palest grey); and 0.0l ⁇ P-value ⁇ 0.05 green (paler grey).
  • Figure 10 tabulates the results showing the risk reduction for lipid species ratios all LIPID individuals (statin treated and untreated), females, T2D and non-T2D in stroke (Figure 10A), all CVE (Figure 10B), CVD death (Figure 10C) and MI ( Figure 10D) and to determine lipid biomarkers of therapy responders and therapy non-responders in the absence of treatment.
  • Figure 11 is a schematic representation showing the omega 3 and omega 6 fatty acids and their relationships as described in Example 5.
  • Table 1 provides details of conditions for tandem mass spectrometry of lipid species.
  • Table 2 provides baseline characteristics of the LIPID cohort.
  • lipid species includes a single lipid species, as well as two or more lipid species; reference to “an agent” includes one agent, as well as two or more agents; reference to “the disclosure” includes single and multiple aspects of the disclosure and so forth.
  • LDL-C low-density lipoproteins cholesterol
  • HMG-CoA 3 -hydroxy-3 -methyl -glutary 1 coenzyme A reductase inhibitors
  • statin therapy has not produced the desired reduction in cardiovascular events even after reducing the LDL-C levels, (Olsson et ah, Eur. Heart J: 26:890-896, 2005, Puri et ah, Circulation ⁇ .128:2395-2403, 2013). This suggests additional mechanisms other than change in LDL-C are needed to explain the statin treatment effect and underpin new methods of treatment.
  • the present description enables a lipidomic approach for determining the statin therapy responder status of an individual.
  • the approach is predicated in part on the determination that non-steroidal plasma lipid profiles can be used to stratify individuals as therapy responders or non-responders to statin treatment.
  • therapy responder or responder is meant that the individual is likely to respond to a HMG-CoA reductase inhibitor treatment by displaying or benefiting from a relative risk reduction in a future cardiovascular event.
  • therapy non responder or non-responder is meant that the individual is not likely to respond to HMG-CoA reductase inhibitor treatment by displaying or benefiting from a relative risk reduction in a future cardiovascular event.
  • the statin therapy responder status of an individual is determined based upon the "baseline" or current lipid profile without directly assessing the individual's lipid profile change in response to statin treatment as part of the method.
  • statin therapy responder status of an individual is determined based upon the "baseline" lipid profile and the profile obtained after directly assessing the individual's lipid profile in response to a HMG-CoA reductase inhibitor treatment.
  • An individual's lipid profile may be assessed after statin treatment such as within days, weeks or months of treatment. In one embodiment assessment is within 2 to 6, 1 to 10, 3 to 4 weeks.
  • a method for determining the likelihood that a HMG-CoA reductase inhibitor treatment will reduce the risk of a cardiovascular event in an individual comprising: (i) detecting a level of one or two or more non steroidal lipid species in a biological sample obtained from the individual at a time point before or after treatment; (ii) comparing the level one or two or more lipid species, or a ratio of the level of two lipid species, from step (i) in the sample to a reference level or ratio for the lipid species; and (iii) determining whether the treatment is likely or not to reduce the risk of the cardiovascular event in the individual on the basis of the comparison.
  • the individual can be stratified as a statin therapy responder or non-responder.
  • level is used herein to include a concentration, relative amount, or other signature indicative of an amount or relative amount of a lipid species present in a blood plasma sample obtained from an individual at given time point.
  • the level of a lipid species may be determined directly such as by liquid chromatography electrospray ionization and tandem mass spectrometry using internal standards or indirectly, such as by assessing the level of a reporter molecule that is bound to a lipid species.
  • Non-steroidal means a lipid species other than a lipid species characterized by a fused ring system, such as cholesterol, the sex hormones and adrenocorticoid hormones such as cortisol.
  • biological sample includes a biological material such as whole blood, serum, plasma or other biological fluid, or a solid or semi-solid sample. Samples may be diluted or concentrated, treated or untreated.
  • reference ratio or level includes data or a control a skilled person would use to facilitate the accurate interpretation of technical data.
  • reference ratios or levels are obtained from an individual at an earlier or later time point than for test ratios or levels.
  • reference levels may be pre-determined or pre-selected.
  • Reference levels may be expressed as a median, mode or mean level or range from an individual or a cohort of subjects or a mean together with standard deviation to determine suitable threshold or cut off levels. Reference levels may be expressed in any form such as by concentration or molality.
  • Reference to a "subject” or “individual” includes any human, primate, mammalian or other species of veterinary importance, or test organism known to the skilled person.
  • the level of one or two or more non-steroidal lipid species is determined in a biological sample obtained from the individual at a time point before or after treatment.
  • the lipid species are non-steroidal lipid species selected from those set out in Figure 8.
  • the lipid species comparing step is an iterative process wherein different lipid species are compared sequentially according to a prognostic algorithm.
  • a cardiovascular event is selected from the group consisting of coronary heart disease, atherosclerosis, stroke, cardiomyopathy, cardiovascular disease, ischaemic heart disease, heart failure, hypertensive heart disease, inflammatory heart disease and valvular heart disease.
  • reference to CVE includes an associated event such as one or more forms of stroke.
  • the individual has previously experienced a cardiovascular event.
  • the individual has been previously identified as at risk for a CVE.
  • the lipid species is/are selected from a lipid class or subclass selected from the group consisting of dihydroceramide (Cer(dl8:0)), ceramide (Cer(dl8: l)), monohexocylceramide (HexCer), dihexosylceramide (Hex2Cer), trihexosylceramide (Hex3Cer), GM3 ganglioside (GM3), sphingomyelin (SM), phosphatidylcholine (PC), alkylphosphatidylcholine (PC(O)), alkenylphosphatidylcholine (PC(P)), lysophosphatidylcholine (LPC), lysoalkylphosphatidylcholine (LPC(O)), phosphatidylethanolamine (PE), alkylphosphatidylethanolamine (PE(O)), alkenylphosphatidylethanolamine (PE(P)), ly
  • the method comprises determining or determining and comparing the level of at least 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 or more lipid species including 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 ,
  • the number of ratios determined or determined and compared is between one and one hundred such as 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 or more lipid species including 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, .73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, or 99 ratios.
  • Illustrative methods capable of analysing multiple lipid species include classical lipid extraction methods, mass spectrometry together with electrospray ionization and matrix-assisted laser desorption ionisation, with mass analysis such as quadruple and/or TOF (e.g,. Quadrapole/TOF) or orbitrap mass analysers.
  • Chromatographic methods are used for the separation of lipid mixtures such as gas chromatography, high pressure liquid chromatography (HPLC), ultra-high pressure liquid chromatography (UHPLC), capillary electrophoresis (CE). These may be used with mass spectrometry based detection systems or other detectors including optical detectors.
  • Clinical mass spectrometry systems are used by clinical laboratories to provide lipid profiles and ratios upon request.
  • Another suitable technique for quantitative lipid analysis is one or two dimensional nuclear magnetic resonance (NMR).
  • Two dimensional techniques such as heteronuclear single quantum coherence (HSQC) are suitable for lipid profiling through the ability to elucidate C-H bonds within a structure.
  • HSQC heteronuclear single quantum coherence
  • Lipid level data may be processed to produce a report of levels and/or ratios.
  • lipid data are processed as described herein to identify and/or report the therapy responder or non-responder status of an individual.
  • the methods enabled herein permit integration into pathology architecture or platform systems.
  • the method described herein allows a user or client to determine the statin therapy responder status of an individual, the method including: (a) receiving data in the form of lipid levels, relative lipid levels or signature profiles developed from an individual's plasma sample before or after treatment from the user via a communications network; (b) processing the individuals data via an algorithm which provides therapy responder value (risk reduction) by comparing levels and/or ratios of lipid levels to those from one or more reference levels or ratios.
  • an indication of the responder status of the individual to the user is transferred via a communications network.
  • the end stations can be hand-held devices, such as PDAs, mobile phones, or the like, which are capable of transferring the subject data to the base station via a communications network such as the Internet, and receiving the reports.
  • a server is generally a client server or more particularly a simple object application protocol (SOAP).
  • SOAP simple object application protocol
  • the method is suitable to be practised as a point-of-care method typically employing a device suitable for point of care.
  • Biosensor technologies that permit less expensive equipment or trained personnel are available for developing devices for lipid species analysis that may be used at point of care.
  • Biosensors which recognise a target molecule and produce a measurable or observable signal may be for example, optical, electrochemical or mechanical biosensors.
  • Assays that use a label indirectly measure the binding of an analyte lipid to a target molecule using a reporter molecule as an indication of binding and amount.
  • Label free assays measure signal changes directly associated with target binding or cellular processes. Examples of label free optical sensors include surface plasmon resonance sensing (SPR), Interferometry (such as backscattering inferometry (BSI), ellipsometry, and assays based on UV absorption of lipid-functionalized gold nanorods.
  • SPR surface plasmon resonance sensing
  • Interferometry such as backscattering inferometry (BSI)
  • ellipsometry ellipsometry
  • the target lipid molecule is immobilized on the surface of a biosensor and then probed with a binding agent, such as an antibody couples to a label
  • a binding agent such as an antibody couples to a label
  • Electrochemical sensors use an electrode to directly detect a reaction, typically a current from electron transfer during binding of an analyte and a chemically functionalized surface. Potentiometric sensors usefully measure charge accumulation to detect lipid antigens such as amphiphilic cholesterol using lipid films.
  • Mechanical sensors are ideal for clinical applications and include cantilever and quartz crystal microbalances (QCM). The later detects changes in resonance frequency on the sensor surface from increased mass due to analyte binding.
  • the method is an enzyme-linked immunosorbent (ELISA)-type, flow cytometry, bead array, lateral flow, cartridge, microfluidic or immunochromatographic based method or the like.
  • ELISA enzyme-linked immunosorbent
  • binding agents such as an antibody or an antigen-binding fragment thereof.
  • suitable binding agents include antigen binding constructs such as affimers, aptamers, or suitable ligands or parts thereof.
  • Antibodies such as monoclonal antibodies, or derivatives or analogs thereof, include without limitation: Fv fragments; single chain Fv (scFv) fragments; Fab' fragments; F(ab')2 fragments; humanized antibodies and antibody fragments; camelized antibodies and antibody fragments, and multivalent versions of the foregoing.
  • Multivalent binding reagents also may be used, as appropriate, including without limitation: monospecific or bispecific antibodies; such as disulfide stabilized Fv fragments, scFv tandems (scFv) fragments, diabodies, tribodies or tetrabodies, which typically are covalently linked or otherwise stabilized (i.e. leucine zipper or helix stabilized) scFv fragments.
  • Antigen-specific binding agents including antibodies and their derivatives and analogs and aptamers
  • Polyclonal antibodies can be generated by immunization of an animal.
  • Monoclonal antibodies can be prepared according to standard (hybridoma) methodology.
  • Antibody derivatives and analogs, including humanized antibodies can be prepared recombinantly by isolating a DNA fragment from DNA encoding a monoclonal antibody and subcloning the appropriate V regions into an appropriate expression vector according to standard methods. Phage display and aptamer technology is described in the literature and permit in vitro clonal amplification of antigen-specific binding reagents with very affinity low cross-reactivity.
  • Phage display reagents and systems are available commercially, and include the Recombinant Phage Antibody System (RPAS), commercially available from Amersham Pharmacia Biotech, Inc. of Piscataway, New Jersey and the pSKAN Phagemid Display System, commercially available from MoBiTec, LLC of Marco Island, Florida. Aptamer technology is described for example and without limitation in US Patent Nos. 5,270,163; 5,475,096; 5,840,867 and 6,544,776.
  • RPAS Recombinant Phage Antibody System
  • the method comprises determining lipid species levels in a plasma sample taken from an individual before treatment.
  • the individual is HMG- CoA reductase inhibitor treatment naive.
  • Lipid level data may be subjected to an algorithm to integrate the new data with reference levels of corresponding lipid species from reference individuals or the individual at an earlier time point, and with any relative risk reduction for future a cardiovascular event.
  • baseline lipid species are used to predict the response of an individual to statin treatment before treatment, that is, in the absence of specific HMG-CoA reductase inhibitor administration.
  • a method for determining the likelihood that a HMG-CoA reductase inhibitor treatment will reduce the risk of a cardiovascular event in an individual comprising: (i) detecting a level of one or two or more non steroidal lipid species in a biological sample obtained from the individual at a time point before treatment; (ii) comparing the level one or two or more lipid species, or a ratio of the level of two lipid species, from step (i) in the sample to a reference level or ratio for the lipid species; and (iii) determining whether the treatment is likely or not to reduce the risk of the cardiovascular event in the individual on the basis of the comparison.
  • RRR relative risk reduction
  • All individuals to assess relative risk reduction
  • females to assess relative risk reduction
  • non-type 2 diabetes individuals to assess relative risk reduction
  • type 2 diabetes individuals to assess relative risk reduction
  • Each group was stratified into quartiles based on the lipid ratios and the difference in the relative risk reduction (RRR) allocated between Ql and Q4. This allows determination where a change in the level of a single lipid species is associated with a reduced risk of a cardiovascular event.
  • Lipid ratios are selected if the difference in RRR between Ql and Q4 is greater than about 50% in all groups (for CVD death), greater than 35% in all groups (for CVE), greater than 40% in all groups (for MI), greater than 60% in all groups (for stroke).
  • Lipid species within all selected lipid ratios are examined and those lipid species that appear more than once are considered treatment biomarkers and included in the final lipid list.
  • lipid biomarkers used to predict the RRR response to statin treatment include predominantly species of phosphatidylcholine (including lyso and ether species), phosphatidylinositol, and sphingomyelin. Lipid species of dihexosylceramide and triacylglycerol were also identified as useful.
  • biomarker lipid species are selected from or include one or more of namely Hex2Cer(l6:0), LPC(l6: l), LPC(20:l), PC(3 l : l), PC(32:2), PC(32:3), PC(33:2), PC(33:3), PC(34:0), PC(34: l), PC(35:3), PC(36:3), LPC(0-22: l), LPC(0-24: l), PC(0-34:3), PI(34:0), PI(36:4), PI(38:2), PI(38:6), SM(34: l), SM(35:2), SM(36: l), SM(36:2), SM(36:3), SM(37:2), and TG(l8:0/l8:0/l8:0).
  • reference to CVE includes an associated event such as one or more forms of stroke.
  • Lipid species can be categorised as those that are elevated or those that are reduced in statin therapy responders or statin non-responders. In one embodiment, these lipid biomarkers are selected when considering statin response and risk reduction in terms of mycardial infarction (MI), cardiovascular disease (CVD) death, stoke and all cardiovascular events (CVE).
  • MI mycardial infarction
  • CVD cardiovascular disease
  • CVE all cardiovascular events
  • lipid species are selected from or include one or more of namely LPC(l6: l), LPC(20: l), PC(32:2), LPC(0-22: l), PI(36:4), PI(38:2), PI(38:6), SM(35:2), SM(36: l), SM(36:2), SM(37:2), and TG(l8:0/l8:0/l8:0).
  • Lipid species can be categorised as those that are elevated or those that are reduced in statin therapy responders or statin non- responders. In one embodiment, these lipid biomarkers are selected when considering statin response and risk reduction in terms of mycardial infarction (MI), cardiovascular disease (CVD) death, and all cardiovascular events (CVE).
  • MI mycardial infarction
  • CVD cardiovascular disease
  • CVE all cardiovascular events
  • lipid species for ratio calculations are selected one from each category (elevated or reduced) to maximise the diagnostic potential of the assessment.
  • one or two or more different classes or sub classes are selected in step (ii).
  • the class or subclass is selected in step (ii) from a phosphatidylcholine (including lyso and ether species), a phosphatidylinositol, a sphingomyelin, a dihexosylceramide and a triacylglycerol.
  • the lipid species is a phospholipid selected from the group consisting of lysophosphatidylcholine, sphingomyelin, phosphatidylinositol, phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, ly sophosphati dy 1 ethal ol amine .
  • the method step (i) is conducted before a HMG-CoA reductase inhibitor treatment.
  • the lipidomic profile of one, two or more lipid species or at least one ratio of the level of two lipid species is assessed in the absence of a HMG- CoA reductase inhibitor treatment to determine whether statin treatment is likely or not to reduce the risk of the cardiovascular event in the individual on the basis of the comparison between the baseline level or ratio and a reference level or profile such as a predetermined threshold, ratio, level or cut off.
  • step (i) is conducted before a HMG-CoA reductase inhibitor treatment and wherein the lipid species in at least one ratio of the level of two lipid species in step (ii) are selected from Hex2Cer(l6:0), LPC(l6: l), LPC(20: l), PC(3 l :l), PC(32:2), PC(32:3), PC(33:2), PC(33:3), PC(34:0), PC(34: l), PC(35:3), PC(36:3), LPC(0-22: l), LPC(0- 24: 1), PC(0-34:3), PI(34:0), PI(36:4), PI(38:2), PI(38:6), SM(34: l), SM(35:2), SM(36: l), SM(36:2), SM(36:3), SM(37:2), and TG(l8:0/l8:0/l8/l8
  • step (i) is conducted before a HMG-CoA reductase inhibitor treatment and wherein the one, two or more lipid species in step (ii) are selected from Hex2Cer(l6:0), LPC(l6: l), LPC(20: l), PC(3l : l), PC(32:2), PC(32:3), PC(33:2), PC(33:3), PC(34:0), PC(34: l), PC(35:3), PC(36:3), LPC(0-22: l), LPC(0-24: l), PC(0-34:3), PI(34:0), PI(36:4), PI(38:2), PI(38:6), SM(34: l), SM(35:2), SM(36: l), SM(36:2), SM(36:3), SM(37:2), and TG(l8:0/l8:0/l8:0).
  • step (i) is conducted before a HMG-CoA reductase inhibitor treatment and wherein the one, two or more lipid species in step (ii) are selected from LPC(l6: l), LPC(20: l), PC(32:2), LPC(0-22: l), PI(36:4), PI(38:2), PI(38:6), SM(35:2), SM(36: l), SM(36:2), SM(37:2), and TG(l8:0/l8:0/l8:0).
  • step (i) is conducted before a HMG-CoA reductase inhibitor treatment and wherein the lipid species in at least one ratio of the level of two lipid species in step (ii) are selected from LPC(l6: l), LPC(20: l), PC(32:2), LPC(0-22: l), PI(36:4), PI(38:2), PI(38:6), SM(35:2), SM(36: l), SM(36:2), SM(37:2), and TG(l8:0/l8:0/l8:0).
  • steps (i) to (iii) are repeated after a treatment.
  • step (i) is conducted after a HMG- CoA reductase inhibitor treatment.
  • a HMG- CoA reductase inhibitor treatment may be a "test" treatment conducted for example prior to deciding whether or not to proceed with a HMG-CoA reductase inhibitor treatment of an individual.
  • the administered treatment may be part of a current or recent treatment regimen, the effects of which are sought to be determined.
  • the individual may be naive to HMG-CoA reductase inhibitor treatment or the individual may have a history of treatment or a current or on-going experience of HMG-CoA reductase inhibitor treatment.
  • a method for determining the likelihood that a HMG-CoA reductase inhibitor treatment will reduce the risk of a cardiovascular event in an individual comprising: (i) detecting a level of one or two or more non steroidal lipid species in a biological sample obtained from the individual after the treatment; (ii) comparing the level one or two or more lipid species, or a ratio of the level of two lipid species, from step (i) in the sample to a reference level or ratio for the lipid species; and (iii) determining whether the treatment is likely or not to reduce the risk of the cardiovascular event in the individual on the basis of the comparison.
  • HMG-CoA reductase inhibitor treatment was associated with changes in 191 lipid species independent of changes in clinical lipids (total cholesterol, HDL-C and triglycerides).
  • Species containing arachidonic acid showed a positive association while species of phosphatidylinositol were negatively associated.
  • a larger decrease in the phosphatidylinositol species (PI(36:2)) and a larger increase in the phosphatidylcholine species (PC(38:4)) were associated with fewer future cardiovascular events after adjustment for several risk factors including change in LDL-C.
  • Reference to an HMG-CoA reductase inhibitor treatment regimen includes administration of compositions that may vary for example in terms of a particular formulation or species of HMG-CoA reductase inhibitor, or administration of a composition at a particular dose or frequency. Once the results of a particular treatment are assessed using the instant method, different compositions and treatments regimen such as using an increased or a decreased dose may be indicated. A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
  • Specific treatments include 40mg pravastatin daily but multiple dosing regimens are known in the art for statins.
  • the HMG-CoA reductase inhibitor is a statin selected from synthetic or naturally occurring inhibitors and may be selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.
  • a reference level is from a sample from the same individual taken at an earlier time point.
  • step (i) is conducted after a HMG-CoA reductase inhibitor treatment and wherein at least one lipid species is a lipid species such as a phospholipid species or a phosphatidylinositol lipid species that displays a reduced level as a result of the treatment in reference individuals who also show a reduced the risk of a cardiovascular event as a result of the treatment.
  • a lipid species such as a phospholipid species or a phosphatidylinositol lipid species that displays a reduced level as a result of the treatment in reference individuals who also show a reduced the risk of a cardiovascular event as a result of the treatment.
  • exemplary species are set out in Figure 8 or 9.
  • step (i) is conducted after a HMG-CoA reductase inhibitor treatment and wherein at least one lipid species is a phosphatidylcholine species or a lipid species comprising arachidonic acid (20:4) or a precursor (20:3) that displays an elevated level as a result of the treatment in reference individuals who also show a reduced risk of a cardiovascular event as a result of the treatment.
  • at least one lipid species is a phosphatidylcholine species or a lipid species comprising arachidonic acid (20:4) or a precursor (20:3) that displays an elevated level as a result of the treatment in reference individuals who also show a reduced risk of a cardiovascular event as a result of the treatment.
  • exemplary species are set out in Figure 8 or 9.
  • step (i) is conducted after a HMG-CoA reductase inhibitor treatment
  • the method comprises detecting the level of two or more lipid species in the sample.
  • lipid species are selected from two or more different lipid classes or subclasses.
  • a ratio in step (iii) is between the level of two lipid species selected from Figure 9.
  • a ratio in step (iii) is between the level of two lipid species selected from a lipid classes or sub classes selected from Figure 9.
  • a ratio in step (iii) is between (a) the level of a phosphatidylinositol species that displays reduced levels as a result of the treatment in reference individuals who also show a reduced the risk of a cardiovascular event as a result of the treatment and (b) a phosphatidylcholine species that displays an elevated level as a result of the treatment in reference individuals who also show a reduced risk of a cardiovascular event as a result of the treatment.
  • the change in the PLPC lipid ratio of selected lipid species after test treatment is used to predict the relative risk reduction an individual is likely to receive from the treatment.
  • step (i) is conducted after a HMG-CoA reductase inhibitor treatment wherein a ratio in step (iii) is between the level of PI(36:3) and PC(38:4) and/or between the level of PI(36:2) and PC(38:4).
  • the present description provides a method for stratifying an individual as a likely therapy responder or likely non-responder with respect to a HMG-CoA reductase inhibitor treatment regimen, the method comprising ascertaining the likelihood that the HMG-CoA reductase inhibitor treatment regimen will reduce the risk of a cardiovascular event in the individual according to the herein described method comprising: (i) detecting a level of one or two or more non-steroidal lipid species in a biological sample obtained from the individual at a time point before or after treatment; (ii) comparing the level one or two or more lipid species, or a ratio of the level of two lipid species, from step (i) in the sample to a reference level or ratio for the lipid species; and (iii) determining whether the treatment is likely or not to reduce the risk of the cardiovascular event in the individual on the basis of the comparison.
  • the present methods will find broad application in clinical studies for subject stratification and surrogate endpoint determinations for clinical trials and drug screening protocols.
  • the present description provides method of screening for an agent that reduces the risk of a cardiovascular event, the method comprising screening agent/s for an ability to: (i) reduce the level of a phophosphatidylinositol lipid species in a test subject or (ii) establish a statin therapy responder or non-responder lipid profile as identified herein.
  • an agent is pharmaceutical agents include small organic molecules such as drug compounds (e.g., compounds approved for human or veterinary use), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells.
  • drug compounds e.g., compounds approved for human or veterinary use
  • peptides e.g., compounds approved for human or veterinary use
  • proteins include small organic molecules such as drug compounds (e.g., compounds approved for human or veterinary use), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins,
  • the present description enables a method of treatment or prophylaxis comprising administering an HMG-CoA reductase inhibitor treatment regimen to reduce the risk of a cardiovascular event, the method comprising administering an HMG-CoA reductase inhibitor treatment regimen after ascertaining the likelihood that the HMG-CoA reductase inhibitor treatment regimen will reduce the risk of a cardiovascular event in the individual according to the herein described method.
  • Reference to an HMG-CoA reductase inhibitor treatment regimen includes administration of compositions that may vary for example in terms of a particular formulation or species of HMG-CoA reductase inhibitor, or administration of a composition at a particular dose or frequency. Once the results of a particular treatment are assessed using the instant method, different compositions and treatments regimen such as using an increased or a decreased dose may be indicated. A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
  • the HMG-CoA reductase inhibitor is a statin selected from synthetic or naturally occurring inhibitors and may be selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.
  • a method of treatment or prophylaxis comprising administering an HMG-CoA reductase inhibitor to reduce the risk of a cardiovascular event, the method comprising administering an HMG-CoA reductase inhibitor after ascertaining the likelihood that the HMG-CoA reductase inhibitor treatment will reduce the risk of a cardiovascular event in the individual, the method of ascertaining comprising: (i) detecting a level of one or two or more non-steroidal lipid species in a biological sample obtained from the individual at a time point before or after treatment; (ii) comparing the level one or two or more lipid species, or a ratio of the level of two lipid species, from step (i) in the sample to a reference level or ratio for the lipid species; and (iii) determining whether the treatment is likely or not to reduce the risk of the cardiovascular event in the individual on the basis of the comparison.
  • an alternative agent may be selected from a PCSK9 inhibitor, - Bile acid sequestrants, Ezetimibe (or NPC1L1 blockers), niacin, phytosterol, a behavioural or dietary modification (including physical activity) and the like.
  • steps (i) to (iii) are repeated after a treatment.
  • the disclosure enables a method of treatment or prophylaxis including co-administration of a HMG-CoA reductase inhibitor treatment and a fatty acid selected from an omega-6 fatty acid or arachidonic acid.
  • HMG-CoA reductase inhibitor treatment in combination with fatty acid supplementation enhances responsiveness to statins and/or provides treatment or prophylaxis of CVE and/or stoke.
  • the description enables a method of treatment or prophylaxis to reduce the risk of a cardiovascular event comprising administering an HMG-CoA reductase inhibitor agent in combination with a fatty acid agent such as omega-6 fatty acid or arachidonic acid.
  • a fatty acid agent such as omega-6 fatty acid or arachidonic acid.
  • the combination treatment is advanced based on the results of testing according to the methods described herein.
  • the description enables a method of treatment or prophylaxis to reduce the risk of a cardiovascular event comprising administering an HMG-CoA reductase inhibitor agent in combination with a fatty acid agent such as omega-6 fatty acid or arachidonic acid after ascertaining the likelihood that the HMG- CoA reductase inhibitor treatment regimen will reduce the risk of a cardiovascular event in the individual according to the herein described method.
  • references to "in combination” and “co-administration” includes simultaneous or sequential administration of an HMG-CoA reductase inhibitor and fatty acid supplementation such as omega-6 fatty acid or arachidonic acid, and administration of a formulation comprising one or more of both agents.
  • Regimes may be selected based upon the individual and/or the desired therapeutic and/or prophylactic effect to be achieved, and the exigencies of the situation.
  • omega 6 fatty acid is selected from species within the metabolicpathway 08:2, 18:3, 20:3, 20:4, 22:4, 24:4, 24:5 and 22:5.
  • the additional agents may also be administered together with each other and/or with the HMG-CoA reductase inhibitor in a single dose or administered separately in different doses.
  • the particular combination to employ in a regimen will take into account compatibility of the HMG- CoA reductase inhibitor and fatty acid. In general, it is expected that the agent(s) utilized in combination are utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
  • kits e.g., pharmaceutical packs.
  • the kits provided may comprise of the HMG-CoA reductase inhibitor and fatty acid supplement and a container (e.g., a vial and/or dispenser package, or other suitable container).
  • a container e.g., a vial and/or dispenser package, or other suitable container.
  • provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of an active agent.
  • agents provided in a first container and a second container is combined to form one unit dosage form.
  • the kits may contain separate agents in separate containers together with instructions for use in combination such as simultaneously or sequentially.
  • the present description provides method of treating a subject at risk of a cardiovascular event, the method comprising administering an agent that lowers the plasma levels of phosphatidylinositol or phosphatidylinositol synthase in the subject.
  • Down regulation of phophosphatidylinositol may be achieved in a subject by administration of phosphatidylinositol synthase (CIDPT/PISI) inhibitor or of another enzyme in the biosynthetic pathway.
  • CIDPT/PISI phosphatidylinositol synthase
  • CIDPT inhibitors are selected from inositol analogues (such as chlorinated analogues of inositol, 3-substituted lD-myo inositol), an anti-CDIPT antibody or antigen binding part thereof that is a phosphatidylinositol synthase inhibitor, an aptamer, small molecule, an RNA such as an editing, ribozyme, antisense or inhibitory RNA, zinc such as zinc oxide in the case of zinc deficiency.
  • inositol analogues such as chlorinated analogues of inositol, 3-substituted lD-myo inositol
  • an anti-CDIPT antibody or antigen binding part thereof that is a phosphatidylinositol synthase inhibitor, an aptamer, small molecule, an RNA such as an editing, ribozyme, antisense or inhibitory RNA, zinc
  • Antibody or natural product inhibitory agents are known in the art and are clearly contemplated herein.
  • agents are based on nucleic acids and include for example antisense oligonucleotides, ribozymes and small inhibitory RNAs. There molecules act to inhibit expression of a gene encoding a target enzyme whose activity facilitates phophosphatidylinositol production.
  • Nucleic acids may be single stranded or double stranded, or may contain portions of both double stranded and single stranded sequences.
  • the nucleic acid may be DNA, both genomic and cDNA, RNA, or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine and isoguanine.
  • Nucleic acids may be synthesized as a single stranded molecule or expressed in a cell using a synthetic gene. Nucleic acids may be obtained by chemical synthesis methods or by recombinant methods.
  • the nucleic acid may also be a RNA such as a mRNA, tRNA, short hairpin RNA (shRNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), transcriptional gene silencing RNA (ptgsRNA), Piwi-interacting RNA, pri-miRNA, pre-miRNA, micro-RNA (miRNA), or anti-miRNA, as known in the art.
  • RNA such as a mRNA, tRNA, short hairpin RNA (shRNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), transcriptional gene silencing RNA (ptgsRNA), Piwi-interacting RNA, pri-miRNA, pre-miRNA, micro-RNA (miRNA), or anti-miRNA, as known in the art.
  • the nucleic acid may also be an aptamer which refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target.
  • Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by Exponential Enrichment), disclosed in ET.S. Pat. No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries.
  • Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules.
  • the nucleotide components of an aptamer may have modified sugar groups (e.g., the 2'— OH group of a ribonucleotide may be replaced by 2'-F or 2'-NH.sub.2), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood.
  • Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system.
  • Intramers and spegelmers are also contemplated.
  • an aptamer which is expressed in vivo For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes.
  • Spiegelmer are also aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.
  • a nucleic acid will generally contain phosphodiester bonds, although nucleic acid analogs may be included that may have at least one different linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphosphoroamidite linkages and peptide nucleic acid backbones and linkages.
  • Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those disclosed in U.S. Pat. Nos. 5,235,033 and 5,034,506.
  • Nucleic acids containing one or more non-naturally occurring or modified nucleotides are also included within the definition of nucleic acid.
  • the modified nucleotide analog may be located for example at the 5'-end and/or the 3'-end of the nucleic acid molecule.
  • Antisense oligonucleotides which may be RNA or DNA, would act to directly block the translation of CIDPT RNA by binding thereto and thereby preventing protein translation or increasing mRNA degradation, thus decreasing the level of CIDPT.
  • antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the mRNA transcript sequence encoding CIDPT can be synthesized, e.g., by conventional phosphodiester techniques and administered by e.g., intravenous injection or infusion. Methods for using antisense techniques for specifically inhibiting gene expression of genes whose sequence is known are well known in the art. It should be further recalled that antisense oligonucleotides may be modified with phosphorothioate to prevent their in vivo hydrolysis by nucleases. Such modifications are well known in the art.
  • Small inhibitory RNAs can also function as inhibitors of CIDPT expression for use in the instant methods.
  • CIDPT gene expression can be reduced by contacting the individual with a small double stranded RNA (dsRNA), or a vector or construct causing the production of a small double stranded RNA, such that CIDPT gene expression is specifically inhibited (i.e. RNA interference or RNAi).
  • dsRNA small double stranded RNA
  • RNAi RNA interference
  • Methods for selecting an appropriate dsRNA or dsRNA-encoding vector are well known in the art for genes whose sequence is known.
  • Ribozymes can also function as inhibitors of CIDPT gene expression for use in the present methods.
  • Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
  • the mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.
  • Engineered hairpin or hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of CIDPT mRNA sequences are thereby useful within the scope of the present invention.
  • ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, which typically include the following sequences, GUA, GUU, and GUC. Once identified, short RNA sequences of between about 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render the oligonucleotide sequence unsuitable. The suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using, e.g., ribonuclease protection assays.
  • compositions are conveniently prepared according to conventional compounding techniques. See for example Remington's Pharmaceutical Sciences 18* Edition Mack Publishing Company Easton PA ETSA 1009. Compositions may comprise one or more active agents/sub stances, together with acceptable excipient, carrier, diluents, buffer, stabilizer, or other materials well known in the art.
  • the carrier may take a wide variety of forms depending upon the form of preparation desired for administration, e.g., intravenous, oral or parenteral.
  • compositions or combination of compositions is generally administered for a time and under conditions sufficient to elicit a minimum beneficial response and then continued optionally with monitoring as described herein. Accordingly, compositions may be administered once, or twice, or 5X, or 10X or more times and, similarly administration may be daily, weekly, monthly or less frequently. A broad range of doses may be applicable and the instant methods may be employed to determine the most effective dose/s.
  • the level of non-steroidal lipid species in the individual further characterises the individual’s risk of a comorbid event.
  • a comorbid event may be diabetes, for example.
  • the description further enables a method of treatment or prophylaxis comprising administering an HMG-CoA reductase inhibitor treatment regimen to reduce the risk of a cardiovascular event, the method comprising administering an HMG-CoA reductase inhibitor treatment regimen after ascertaining the likelihood that the HMG-CoA reductase inhibitor treatment regimen will reduce the risk of a cardiovascular event in the individual according to the methods described herein, and administering a second agent to treat or prevent a comorbid event.
  • the second agent is an anti-inflammatory agent, an antithrombotic agent, an anti-platelet agent, a fibrinolytic agent, a thrombin inhibitor, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, an angiotensin system inhibitor, or a peptide hormone.
  • the comorbid event is diabetes and the second agent is insulin.
  • the lipidomic methodology used may be an advance upon earlier targeted methodology developed on an Agilent 1200 liquid chromatography system combined with an Applied Biosystems API 4000 Q/TRAP mass spectrometer (Alshehry el al., Metabolites. 20l5;5:389- 403) (Alshehry et al., Circulation. 2016;134: 1637-1650) (Weir et al. J. Lipid Res. 20l3;54:2898- 2908).
  • Lipidomic analysis may be performed by liquid chromatography electrospray ionisation tandem mass spectrometry on an Agilent 1290 liquid chromatography system combined with an Agilent 6490 triple quadrupole mass spectrometer, utilizing Mass Hunter software.
  • Liquid chromatography may be performed on a Zorbax Eclipse Plus 1.8 pm Cl 8, 50 x 2.1 mm column (Agilent Technologies).
  • Solvents A and B consist of tetrahydrofuran: methanol: water in the ratio (20:20:60) and (75:20:5) respectively, both containing 10 mM ammonium formate. Columns are heated to 50°C and the auto-sampler regulated to 25°C.
  • Lipid species (1 pL injection) are separated under gradient conditions at a flow rate of 400 pL/min.
  • the gradient is as follows; 0% solvent B to 40% solvent B over 2.0 min, 40% solvent B to 100% solvent B over 6.5 min, 0.5 min at 100% solvent B, a return to 0% solvent B over 0.5 min then 0.5 min at 0% solvent B prior to the next injection (total run time of 10 min).
  • the mass spectrometer is operated in dynamic/scheduled multiple reaction monitoring (dMRM) mode. 345 unique lipid species were measured together with 16 stable isotope or non- physiological lipid standards (test lipid species are listed in Figure 8). Mass spectrometer voltages used for the acquisition of data were; fragmentor voltage, 380 V and cell accelerator voltage, 5 V. The collision energy voltage was set individually for each lipid class and subclass and is listed in Table 1. Acquisition windows were set to between 0.7 and 1.76 min depending on the chromatographic properties of the lipid. Further, there were several sets of isobaric lipids which shared the same nominal parent ion mass and also give rise to the same product ions.
  • dMRM dynamic/scheduled multiple reaction monitoring
  • Diacyl- and triacylglycerol Fragmentation of the ammoniated adducts of diacyl- and triacylglycerol leads to the loss of ammonia and a fatty acid. In this context it is important to recognize that for species which contain more than one of the same fatty acid, the loss of that fatty acid will result in an enhanced signal, as it is the end product from two competing pathways. Consequently, for an MRM transition that corresponded to the loss of a fatty acid that was present more than once, this was divided by the number of times that fatty acid was present. While the response factor for different species of triacylglycerol varied substantially, the lack of suitable standards precluded the determination of suitable response factors for each triacylglycerol species.
  • Phosphatidylinositol A single response factor was calculated for all phosphatidylinositol species to account for the use of the phosphatidylethanolamine (PE(l 7:0/17:0)) as the internal standard for this lipid class.
  • PE(l 7:0/17:0) phosphatidylethanolamine
  • a nine point standard curve was created using commercially available phosphatidylinositol (PI(32:0)) and subsequently spiked into solvent containing a fixed concentration of RE(17:0/17:0). The standard curve resulted in a linear response and indicated a response factor of 1.44 for phosphatidylinositol species relative to phosphatidylethanolamine standard. Other lipid species were not corrected.
  • Plasma quality control samples Two types were utilized in this study. Plasma from six healthy volunteers was pooled and split into multiple aliquots. We refer to these samples as plasma quality control (PQC) samples. These samples are then subjected to extraction and LC-MS analysis alongside samples from the study to provide a measure of analytical variability across the study as a whole.
  • PQC plasma quality control
  • lipid extracts were utilized, which were prepared by pooling the lipid extracts from multiple PQC samples using this mixture to prepare multiple aliquots which were referred to as technical quality control (TQC) samples. Analysis of these samples captures only the variation associated with the LC-MS performance. Within the analytical process every twenty plasma samples a PQC and TQC were included.
  • samples were run in multiple batches.
  • An extraction batch consisted 448 plasma samples, 24 PQC, 24 TQC and 12 blank samples (resulting in 27 batches). Two batches were run consecutively between cleaning of the mass spectrometer. A median centering approach was used for correction of the batch effect.
  • the median PQC concentration of each lipid for each batch was used as a reference point to align the samples with the entire cohort. The alignment was performed by calculating a correction factor to adjust the concentration of each PQC lipid in each batch to the median value for all batches.
  • Example 1 Lipid analysis, statistical analysis and Study Population
  • the LIPID Study design has been published in detail elsewhere (The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. . N. Engl. J. Med. 1998;339: 1349-1357.). Study subjects with a previous history of cardiovascular disease (myocardial infarction (MI) or hospital admission for unstable angina) were between 31 to 75 years of age and had plasma total cholesterol level between 4.0 to 7.0 mmol/L and fasting triglycerides ⁇ 5.0 mmol/L. Patients who experienced heart failure were excluded. Before the actual trial, a single-blind placebo run-in phase was conducted for 8 weeks.
  • MI myocardial infarction
  • triglycerides ⁇ 5.0 mmol/L
  • lipids were extracted from lOpL of human plasma using a single phase butanol/methanol extraction. Extractions were performed in batches of 486 which consisted of plasma samples, pooled plasma controls (every 20 samples) and water blanks (every 40 samples). To each sample, lOOpL of the butanol/methanol mix containing internal standards was added and the samples were vortexed and sonicated on a water bath for 1 hour at l8-22°C. Extracts were centrifuged (l6,000xg, 10 min) and the supernatant transferred to 0.2mL micro-inserts in sample vials for analysis.
  • Lipidomic analysis was performed by liquid chromatography, electrospray ionisation- tandem mass spectrometry using a Agilent 1290 liquid chromatography system with a 50mm Zorbax Eclipse Plus 1.8 pm Cl 8 column, combined with an Agilent 6490 triple quadrupole mass spectrometer.
  • the relative concentration of each lipid species was calculated from the area of the resultant chromatograms for the lipid species and the corresponding internal standards.
  • Cox regression models were used in a landmark analysis of either the treatment group only or the whole cohort. The models were adjusted for covariates previously identified as associated with cardiovascular outcomes (Marschner et al. , J. Am. Coll. Cardiol. 2001;38:56-63).
  • the analysis was then repeated adjusting for changes in each lipid species, changes in LDL-C or both in addition to the baseline lipid levels and the interaction between change in lipid species and treatment.
  • the relative risk reduction from pravastatin in these models was used to determine the extent to which the pravastatin treatment effect on subsequent cardiovascular events/deaths was accounted for by changes in each lipid species.
  • the above analysis was repeated for 1000 randomizations of the treatment allocation within each group (pravastatin treatment and placebo) and the percentiles were determined for the treatment effect.
  • the lipid ratio PI(36:2)/PC(38:4) was identified as a sensitive marker of the relative risk reduction afforded by statin treatment. To assess this, the above analyses were repeated on the lipid ratio PI(36:2)/PC(38:4).
  • the LDL-C lowering and RRR by pravastatin treatment were also explored in the quartiles of the lipid ratio in the statin treatment group compared to placebo group.
  • the samples in each quartile of the lipid ratio within the treatment group were pooled together with the entire placebo group and a Cox regression model was fitted to find the relative risk reduction by pravastatin treatment.
  • RRR was also calculated based on the relative risk in the pravastatin group and the placebo group, without using a modelling approach (no adjustments for covariates).
  • the LIPID cohort analysed in this study consisted of 4991 participants with a median (Q1-Q3) age of 64 (57-69) years (details of the study are described in "The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels". . N. Engl. J. Med. 1998; 339: 1349-1357). Plasma samples were collected at both baseline and the one year follow-up. In this cohort, 944 patients experienced cardiovascular events after the one year follow-up and there were 498 cardiovascular deaths (Figure 1). Details of baseline characteristics stratified by outcome in the present sub-cohort are shown in Table 2.
  • Dihydroceramide and lysophosphatidylinositol showed a positive association with treatment after adjustment for changes in clinical lipids, but still showed a decrease in absolute levels (Data not shown).
  • 191 were significantly associated with treatment after correction for multiple comparisons ( Figure 9).
  • Eleven of the 16 phosphatidylinositol species were negatively associated with pravastatin treatment, 2 species were positively associated and three species were not significantly associated.
  • 10 were negatively associated, while 18 were positively associated with treatment.
  • the changes in the lipid species PI(36:2) and PC(38:4) showed significant associations with the treatment (negative and positive associations respectively), and in the opposite directions with future cardiovascular outcomes (positive and negative associations respectively). These species also explain large proportions of the treatment effect for both cardiovascular events and death.
  • the effect of the ratio of PI(36:2)/PC(38:4) in the landmark analysis was also investigated.
  • the percentage change in the ratio of PI(36:2)/PC(38:4) was significantly associated with pravastatin treatment independent of age, gender, BMI and the changes in total cholesterol, HDL-C and triglycerides (Figure 9).
  • the change in the lipid ratio was significantly associated with future cardiovascular events and cardiovascular death, independent of baseline risk factors including change in LDL-C and baseline values of the lipid ratio as indicated by cox regression analysis (Data not given). This association was positive indicating that larger decrease in this lipid ratio was associated with fewer cardiovascular events and deaths.
  • Statins change levels of several plasma lipid classes and individual species and the inventors initially hypothesized that some of the benefits of pravastatin could be explained by this effect and that changes in these same lipid species will identify those who benefit from statin treatment (i.e. receive a relative risk reduction) from those who do not.
  • statin treatment i.e. receive a relative risk reduction
  • 345 lipid species in 4,991 participants were analysed at two time points.
  • the relationship between pravastatin treatment and the change in lipid species from baseline to l-year follow-up was determined.
  • a landmark analysis association of the change in lipid species with future cardiovascular events and cardiovascular deaths independent of changes in LDL-C levels was assessed.
  • Sphingolipid metabolism is impacted by pravastatin treatment
  • Phosphatidylinositol is synthesized by the enzyme CDP-diacylglycerol-inositol 3- phosphatidyltransferase which transfers the phosphodiacylglycerol from the CDP-diacylglycerol onto a myoinositol.
  • phosphatidylcholine which is synthesised by the action of diacylglycerol cholinephosphotransferase, which transfers the phosphocholine group from CDP-choline onto a diacylglycerol.
  • pravastatin down regulates the production of CDP-diacylglycerol leading to an overall downregulation of phosphatidylinositol synthesis.
  • the lipid ratio identified those who do not receive a risk reduction from pravastatin treatment.
  • Association analysis of pravastatin treatment with the change in lipid species identified multiple species that were altered independently of the changes in clinical lipid measures.
  • Two species that showed the strongest negative and positive associations (PI(36:2) and PC(38:4)) were also observed to be associated with cardiovascular outcomes and to explain the largest proportion of the pravastatin treatment effect on outcomes.
  • pravastatin treatment has clinically important effects on lipid metabolism beyond LDL cholesterol reduction and that these effects influence risk of future cardiovascular events.
  • the ability to identify a subset of patients who do not receive a risk reduction from pravastatin treatment despite showing a reduction in LDL-C provides insights into how these patients might best be managed to minimise risk of future events. Further lowering of LDL-C with higher doses or alternate therapies such as PCSK9 inhibitors will lead to both changes in the lipid ratio and reduced risk.
  • the description provides new treatment strategies aimed at modulating either or both of the lipid species within the ratio that will have beneficial effects in this group of patients.
  • the description provides the results of landmark longitudinal analyses of the effects of statins on plasma lipid species and the subsequent influence on cardiovascular risk.
  • the change in phosphatidylinositol and phosphatidylcholine species can explain a large proportion of the pravastatin treatment effect independent of changes in LDL-C.
  • the change in the ratio of two lipid species PI(36:2)/PC(38:4) upon pravastatin treatment quantitates the relative risk reduction from treatment and identified at least 25% of the treatment group that does not receive a reduction in risk of future cardiovascular events. Accordingly, this lipid ratio represents a useful biomarker to monitor statin treatment and reduce the risk of future cardiovascular events.
  • Example 4 Identification of lipid levels that predict an individual's response to a HMG-CoA reductase inhibitor treatment regimen in the absence of HMG-CoA reductase inhibitor administration
  • Baseline lipid ratios were identified that predict response to statin treatment.
  • RRR relative risk reduction
  • Each group was stratified into quartiles based on the lipid ratios and the difference in the relative risk reduction allocated between Ql and Q4. Lipid ratios were selected if the difference in RRR between Ql and Q4 was greater than 50% in all groups (for CVD death), greater than 35% in all groups (for CVE), greater than 40% in all groups (for MI), greater than 60% in all groups (for stroke). Lipid species within all selected lipid ratios were examined and those lipid species that appeared more than once were considered treatment biomarkers and included in the final lipid list.
  • Lipid biomarkers able to predict RRR response to statin treatment include predominantly species of phosphatidylcholine (including lyso and ether species), phosphatidylinositol, and sphingomyelin. Lipid species of dihexosylceramide and triacylglycerol were also identified.
  • Lipid species can be categorised as those that are elevated or those that are reduced in statin therapy responders or statin non-responders. In one embodiment, lipid species for ratio calculations are selected one from each category to maximise the diagnostic potential of the assessment. The results are set out in Figure 10 and lipid species can be selected based upon these results.
  • Example 5 Co-administration of a HMG-CoA reductase inhibitor treatment and PC and/or arachidonic acid supplementation enhances responsiveness to statins and/or provides treatment or prophylaxis of CVE and/or stoke
  • omega 6 fatty acid supplementation in combination with a statin is required in a sizable proportion of the population to achieve a risk reduction from statin treatment.
  • Individuals who do not get an upregulation of omega 6 fatty acid production do not benefit from the statin treatment and so supplementation of omega 6 fatty acids in people using a statin will improve the effect of the statin to reduce their risk of having a cardiovascular event.
  • treatment is proposed for those individuals who are non-responders (i.e., they do not have a natural increase in omega 6 on treatment statins. In the present study at least 25% of the population fell into this category.
  • Omega 6 supplementation includes administration of omega 6 fatty acids including 18:2, 18:3 20:3, 20:4, 22:4, 24:4, 24:5 and 22:5 lipid species.
  • Arachidonic acid (20:4) is biologically active for example, however one or more additional or alternative lipid species along that pathway can also be administered.
  • the complete list of omega-6 fatty acids is set out in Figure 11
  • Example 6 - CIDPT inhibitors or other phosphatidylinositol inhibitors enhances responsiveness to statins and/or provides treatment or prophylaxis of CVE and/or stoke
  • down-regulation of phosphatidylinositol in response to statin treatment is associated with a reduced risk of a cardiovascular event.
  • Downregulation of phosphatidylinositol may be produced by the inhibition of the enzyme phosphatidylinositol synthase (also known as CDP-Diacylglycerol— Inositol 3-Phosphatidyltransferase (CIDPT)) or other enzymes in the biosynthetic pathway.
  • CIDPT phosphatidylinositol synthase
  • Several reports of inhibitors of CIDPT have been made using analogues of inositol (see for example, Nakamura et al Am J physiol.
  • individuals may be treated by treating a subject at risk of a cardiovascular event, by administering an agent that lowers the plasma levels of a phosphatidylinositol in the subject.
  • Agents that inhibit phosphatidylinositol synthase are known in the art and include inositol analogues.
  • An anti-CDIPT antibody or antigen binding part thereof that is a phosphatidylinositol synthase inhibitor is also contemplated.
  • Agents may also be selected from one or more of the following agents using technology that forms part of the common knowledge of the skilled addressee: an aptamer, small molecule, an antisense, sgRNA or iRNA, zinc in the case of zinc deficiency and/or sorbitol or glucose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de détermination de la probabilité qu'un traitement par inhibiteur de la HMG-CoA réductase réduira le risque d'un événement cardiovasculaire chez un individu, le procédé consistant (i) à détecter un niveau d'une ou de deux espèces lipidiques non stéroïdiennes dans un échantillon biologique prélevé chez l'individu à un instant avant ou après le traitement ; (ii) à comparer le niveau d'une ou de deux espèces lipidiques ou plus, ou un rapport du taux de deux espèces lipidiques, de l'étape (i) dans l'échantillon à un niveau ou rapport de référence pour l'espèce lipidique ; et (iii) à déterminer si le traitement est susceptible ou non de réduire le risque de l'événement cardiovasculaire chez l'individu sur la base de la comparaison. L'invention porte sur un procédé de traitement comprenant l'administration d'un régime de traitement par inhibiteur de la HMG-CoA réductase à l'individu après la détermination de la probabilité que le régime de traitement par inhibiteur de la HMG-CoA réductase réduira le risque d'un événement cardiovasculaire chez l'individu au moyen du procédé ci-dessus. L'invention concerne également un procédé de traitement ou de prophylaxie d'un individu pour réduire le risque d'un événement cardiovasculaire, le procédé comprenant l'administration d'un régime de traitement par inhibiteur de la HMG-CoA réductase en combinaison avec une supplémentation en acides gras comprenant un lipide contenant un acide gras oméga-6 ou un régime de traitement par acide arachidonique. L'invention concerne également un procédé de traitement d'un sujet susceptible de développer un événement cardiovasculaire, le procédé comprenant l'administration d'un agent qui abaisse les taux plasmatiques de phosphatidylinositol chez le sujet.
PCT/AU2018/051371 2017-12-20 2018-12-20 Procédé de prédiction d'état de répondeur à une thérapie médicamenteuse et procédés de traitement Ceased WO2019119049A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017905095 2017-12-20
AU2017905095A AU2017905095A0 (en) 2017-12-20 Method of predicting drug therapeutic responder status and methods of treatment

Publications (1)

Publication Number Publication Date
WO2019119049A1 true WO2019119049A1 (fr) 2019-06-27

Family

ID=66992400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2018/051371 Ceased WO2019119049A1 (fr) 2017-12-20 2018-12-20 Procédé de prédiction d'état de répondeur à une thérapie médicamenteuse et procédés de traitement

Country Status (1)

Country Link
WO (1) WO2019119049A1 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127192A2 (fr) * 2006-04-24 2007-11-08 Duke University Approches lipidomiques pour déterminer des phénotypes de réponse à un médicament dans une maladie cardiovasculaire
WO2011063470A1 (fr) * 2009-11-27 2011-06-03 Baker Idi Heart And Diabetes Institute Holdings Limited Biomarqueurs lipidiques pour maladies cardiaques stables et instables
EP2385374A1 (fr) * 2010-05-05 2011-11-09 Zora Biosciences OY Biomarqueurs lipidomiques pour l'athérosclérose et les maladies cardiovasculaires
US20130102582A1 (en) * 2011-10-13 2013-04-25 Ernst J. Schaefer Compositions and methods for treating and preventing coronary heart disease
EP2592423A1 (fr) * 2011-11-08 2013-05-15 Zora Biosciences OY Biomarqueurs lipidomiques pour la prédiction des résultats cardiovasculaires chez des patients atteints de coronaropathie ne prenant pas un traitement par statine
EP2592422A1 (fr) * 2011-11-08 2013-05-15 Zora Biosciences OY Biomarqueurs lipidomiques pour la prédiction des résultats cardiovasculaires chez des patients atteints de coronaropathie prenant un traitement par statine
EP2667197A1 (fr) * 2012-05-25 2013-11-27 Zora Biosciences OY Biomarqueurs à efficacité et spécificité sensibles pour l'inhibition de proprotéine convertase de subtilisine/kexin de type 9 (PCSK9)
WO2014135696A1 (fr) * 2013-03-08 2014-09-12 Zora Biosciences Oy Marqueurs cvd issus d'une lipoprotéine non à densité élevée
WO2014188202A1 (fr) * 2013-05-24 2014-11-27 King's College London Biomarqueurs
CA3002764A1 (fr) * 2015-10-20 2017-04-27 Medimmune, Llc Marqueur pour le diagnostic de la coronaropathie

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127192A2 (fr) * 2006-04-24 2007-11-08 Duke University Approches lipidomiques pour déterminer des phénotypes de réponse à un médicament dans une maladie cardiovasculaire
WO2011063470A1 (fr) * 2009-11-27 2011-06-03 Baker Idi Heart And Diabetes Institute Holdings Limited Biomarqueurs lipidiques pour maladies cardiaques stables et instables
EP2385374A1 (fr) * 2010-05-05 2011-11-09 Zora Biosciences OY Biomarqueurs lipidomiques pour l'athérosclérose et les maladies cardiovasculaires
US20130102582A1 (en) * 2011-10-13 2013-04-25 Ernst J. Schaefer Compositions and methods for treating and preventing coronary heart disease
EP2592423A1 (fr) * 2011-11-08 2013-05-15 Zora Biosciences OY Biomarqueurs lipidomiques pour la prédiction des résultats cardiovasculaires chez des patients atteints de coronaropathie ne prenant pas un traitement par statine
EP2592422A1 (fr) * 2011-11-08 2013-05-15 Zora Biosciences OY Biomarqueurs lipidomiques pour la prédiction des résultats cardiovasculaires chez des patients atteints de coronaropathie prenant un traitement par statine
EP2667197A1 (fr) * 2012-05-25 2013-11-27 Zora Biosciences OY Biomarqueurs à efficacité et spécificité sensibles pour l'inhibition de proprotéine convertase de subtilisine/kexin de type 9 (PCSK9)
WO2014135696A1 (fr) * 2013-03-08 2014-09-12 Zora Biosciences Oy Marqueurs cvd issus d'une lipoprotéine non à densité élevée
WO2014188202A1 (fr) * 2013-05-24 2014-11-27 King's College London Biomarqueurs
CA3002764A1 (fr) * 2015-10-20 2017-04-27 Medimmune, Llc Marqueur pour le diagnostic de la coronaropathie

Similar Documents

Publication Publication Date Title
Weir et al. Plasma lipid profiling in a large population-based cohort [S]
Dong et al. Serum metabolomics study of polycystic ovary syndrome based on UPLC-QTOF-MS coupled with a pattern recognition approach
Wang et al. Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry
JP6262529B2 (ja) 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー
EP2944964B1 (fr) Biomarqueurs lipides pour les maladies cardiaques stables et instables
Tighanimine et al. A homoeostatic switch causing glycerol-3-phosphate and phosphoethanolamine accumulation triggers senescence by rewiring lipid metabolism
US9546994B2 (en) Biomarkers for type 2 diabetes
Jutras et al. Modulation of the phagosome proteome by interferon-γ
Dai et al. Metabolomics of oncogene-specific metabolic reprogramming during breast cancer
JP2022517163A (ja) 臨床的介入のための妊娠の進展および早期流産の評価方法およびその応用
Ademowo et al. Distribution of plasma oxidised phosphatidylcholines in chronic kidney disease and periodontitis as a co-morbidity
Chi et al. Untargeted metabolomics predicts the functional outcome of ischemic stroke
EP3004889B1 (fr) Methode pour determiner le risque d'une maladie cardiovasculaire par la determination de la quantite d'au moins 2 des lipides triacylglycerol, ester de cholesterol et phosphatidylethaolamine
Neighbors et al. Bioactive lipid lysophosphatidic acid species are associated with disease progression in idiopathic pulmonary fibrosis
WO2022059785A1 (fr) Procédé pour prédire la réponse à un inhibiteur de point de contrôle immunitaire
US12313634B2 (en) Methods for prediction and early detection of diabetes
Rizzo et al. Measurement of succinyl-carnitine and methylmalonyl-carnitine on dried blood spot by liquid chromatography-tandem mass spectrometry
Gao et al. Proteomic and metabolomic profiling of plasma predicts immune-related adverse events in older patients with advanced non-small cell lung cancer
Noto et al. Identification of hnRNP-A1 as a pharmacodynamic biomarker of type I PRMT inhibition in blood and tumor tissues
WO2019119049A1 (fr) Procédé de prédiction d'état de répondeur à une thérapie médicamenteuse et procédés de traitement
US20210278391A1 (en) Compositions and methods for treating cardiovascular and metabolic conditions
US20230305027A1 (en) Methods for treating exacerbations of inflammatory respiratory diseases
US20240069040A1 (en) Detection of a relapse in a multiple sclerosis patient
Macioszek et al. A multiplatform metabolomics approach for comprehensive analysis of GIST xenografts with various KIT mutations
KR102520048B1 (ko) 류마티스 관절염의 치료 반응성 예측용 바이오마커

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18890443

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18890443

Country of ref document: EP

Kind code of ref document: A1